• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA tightens rules on 'revolving door' for committee members and experts

EMA tightens rules on 'revolving door' for committee members and experts

May 7, 2015
CenterWatch Staff

The EMA has updated its rules on declarations of interests for scientific committee members and experts. The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The updates also include a revised guide on how to complete the agency’s declaration of interest form.

EMA’s declaration of interest policy aims for a balanced approach by effectively restricting the involvement of experts with possible conflicts of interests in the agency’s work while maintaining EMA’s ability to access the best available expertise.

“The effective management of conflicts of interests is key to ensuring the independence and integrity of the agency’s scientific recommendations,” said Noël Wathion, EMA’s chief policy adviser. “EMA continually reviews its policy to ensure that the rules are fit for purpose.”

EMA considers employment in a pharmaceutical company incompatible with an involvement in agency activities. Whenever a member of a scientific committee or working party informs the agency that he/she intends to work for a pharmaceutical company, the agency will immediately restrict the member from any participation in the evaluation of medicines. If necessary, the agency also will verify whether the integrity of any ongoing or past scientific reviews in which that person was involved could have been compromised. These rules are reflected in the updated policy and in a new guidance document.

In March 2014, the EMA management board endorsed a major revision of EMA’s policy on handling declarations of interest for scientific committee members and experts. The revision took into account input from stakeholders at the agency’s September 2013 public workshop Best expertise v. conflicts of interests: Striking the right balance. It entered into force on January 30, 2015. EMA will continue to review its policy on a regular basis. The current updates build on the agency’s early experience with the revised policy.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing